Portfolio

ImmTORTM has the potential to amplify the efficacy of biologic therapies
Find Out How

Amplifying the efficacy of biologic therapies

Our ImmTORTM platform has the potential to mitigate unwanted immunogenicity in a targeted manner to enable a new generation of effective biologic therapies.

Image

Enzymatic Therapies

Enzymatic therapies driven by ImmTORTM

For many patients that require biologic or enzymatic therapies, the development of an immune response to the drug itself coincides with a loss of efficacy, often forcing them to discontinue treatment. When ImmTOR is co-administered with immunogenic therapeutic enzymes, it has the potential to ameliorate an immune response to the biologic treatment allowing patients to continue to respond to treatment and stay on therapy longer.

Image

Gene Therapy

The potential of ImmTORTM on gene therapy

ImmTOR has the potential to induce adeno-associated virus (AAV) vector-specific immune tolerance, reducing the severity of the body’s immune response to AAV gene therapies and enabling repeat administrations.

Image

AutoImmune Therapies

Autoimmunity addressed by ImmTORTM

The current standard of care for autoimmune diseases is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and maligancies. Our approach to autoimmune disease is designed to restore natural self-tolerance by administering ImmTOR with nanoparticles-encapsulated self-antigens, and avoid the need for chronic and systemic immune suppression.

Pipeline

Indication

Antigen

Stage of Development

Preclinical
Phase 1
Phase 2
Phase 3

Upcoming Milestone

Commercial Rights

Amplifying the Efficacy of Biologic Therapies

Enzymes

Chronic Refractory Gout

0

Pegadricase

0

90

SEL-212

Phase 3 data H2 2022

0

0

IgA nephropathy (IgAN)

0

IgA protease

0

27

IND filing end of 2021

0

0

Gene Therapies

Methylmalonic acidemia (MMA)

0

AAV8

0

27

MMA-101

IND filing end of 2021

0


0

Ornithine Transcarbamylase
deficiency
(OTCD)

0

AAV-hOTC

0

27

SEL-313

IND filing H2 2022

0

0

Pompe disease

0

Undisclosed

0

20

0

0

Duchenne muscular dystrophy (DMD)

0

Undisclosed

0

20

0

0

Limb-girdle muscular dystrophy (LGMD)

0

Undisclosed

0

20

0

0

Restoring self-tolerance in autoimmune diseases

Primary biliary cholangitis

0

PDC-E2

0

15

IND filing H2 2022

0

0

Enzymes

SEL-212

SEL-212 lays the foundations for Selecta’s pipeline of tolerogenic therapies driven by ImmTOR.

Chronic refractory gout is a severe form of inflammatory arthritis characterized by intense inflammation, debilitating pain, and the formation of tophi (painful deposits of urate crystals in joints and soft tissues). SEL-212 is being developed and commercialized through an out-licensing partnership with Swedish Orphan Biovitrum AB (Sobi). 

In partnership with Sobi, SEL-212 is currently being evaluated in a Phase 3 clinical program consisting of two double-blinded, placebo-controlled studies, DISSOLVE I and DISSOLVE II.

IgA Nephropathy

Selecta is developing a candidate for the treatment of IgA nephropathy combining ImmTOR with an immunoglobulin A (IgA) protease to remove deposits of IgA from kidneys and improve markers of renal dysfunction.

IgA nephropathy is a leading cause of chronic kidney disease (CKD) and renal failure with 30-40% of patients reaching end-stage renal disease 20-30 years after the first clinical presentation. IgA nephropathy is a disease with significant unmet medical need characterized by the deposition of the protein immunoglobulin A (IgA) inside the filters (glomeruli) in the kidney which may lead to blood (hematuria) and protein (proteinuria) being present in urine. Preclinical studies have demonstrated treatment with IgA protease clears glomerular IgA1 deposits and associated inflammation and hematuria. 

An IND for IgA nephropathy is expected to be filed the end of 2021.

Gene Therapy

MMA-101

Selecta’s first gene therapy programs, combining ImmTOR with MMA-101, an AAV gene therapy candidate for treatment of methylmalonic acidemia (MMA), is being developed and is expected to enter clinical trials the end 2021.

MMA is a rare metabolic disease that affects the ability of the body to metabolize certain amino acids and fats and may lead to metabolic acidosis and hyperammonemia and long-term complications including feeding problems, developmental delays, intellectual disability and chronic kidney disease.

SEL-313

Selecta’s wholly owned gene therapy program for the treatment of ornithine transcarbamylase (OTC) deficiency is expected to enter the clinic in 2022.

OTC deficiency is a genetic disorder urea cycle that causes ammonia to accumulate in the blood. The most severe form of the disorder presents within the first few days of life. Severe symptoms include inability to control body temperature and breathing rate, seizures, coma, developmental delays and intellectual disability.

Autoimmune

Primary biliary cholangitis (PBC)

Primary biliary cholangitis (PBC) is a chronic, progressive liver disorder that leads to inflammation, damage and scarring of the small bile ducts.

In PBC, the immune system mistakenly attacks tissue in the liver, damaging the small bile ducts. Treatments to help slow the progression and prevent complications in PBC are available; however, these medications ultimately fail to control PBC, and patients require a liver transplant. ImmTOR’s ability to target the liver, shown in animal models of liver injury and inflammation, may be beneficial in the treatment of patients with PBC.

Image

Our Platform

ImmTORTM: Selective Immune Tolerance Technology

ImmTORTM is an immune tolerance platform designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. ImmTORTM has the potential to amplify the efficacy of biologic therapies, including enabling redosing of life saving gene therapies, and to restore self-tolerance in autoimmune diseases.

Partner with us

Learn more about partnership opportunities

Selecta licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout, to Sobi in mid 2020. Selecta has also partnered with leading gene therapy companies, including AskBio and Sarepta Therapeutics to evaluate the potential of ImmTOR to enable redosing of life-saving gene therapies.